About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT07342699

Location-Molecular Integrated Outcomes in 450 Cerebellar Glioma Microsurgical Cases

The goal of this observational study is to learn if refined anatomical location-combined with molecular biomarkers-can predict surgical success and long-term survival in 450 adults and children with c...

Lead sponsor: West China Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

West China Hospital

Age

3 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Pathologically proven cerebellar glioma (hemisphere, vermis, fourth ventricle, or pontocerebellar-angle region) per 2021 WHO CNS classification
•First microsurgical resection performed at our center between January 2014 and January 2024
•Age ≥ 3 years at surgery
•Pre-operative Karnofsky Performance Status (KPS) recorded
•Availability of post-operative contrast MRI for resection-extent calculation
•Minimum required molecular data: IDH1/2 status (immunohistochemistry ± sequencing)
•Continuous follow-up ≥ 6 months after surgery (out-patient visits or telephone confirmation)

Exclusion Criteria

•Brain-stem glioma with secondary cerebellar invasion
•Recurrent or metastatic glioma
•Previous cranial radiation or glioma surgery at another institution
•Palliative resection (\< 20 % of tumor volume removed)
•Missing post-operative MRI or insufficient tissue for mandatory IDH testing
•Follow-up \< 6 months or lost to follow-up before 6-month landmark

Related studies

RECRUITINGEARLY Phase 1

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

NCT05804227 · Gliomas

RECRUITINGPhase 1/2

5G-PEARL: Paxalisib in Malignant Brain Tumours

NCT07391215 · Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)

RECRUITINGEARLY Phase 1

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

NCT05851378 · Adult Gliomas, Mixed

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

NCT06910306 · Recurrent Glioblastoma, Recurrent Gliomas

AI-assisted Diagnosis of Malignant Brain Tumors

NCT07198256 · Gliomas, Brain Metastases, Adult, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 15, 2026Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment450

Start dateJan 2014

Last updatedJan 15, 2026

Condition

Locations shown

West China Hospital of Sichuan University

Chengdu, Sichuan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions